172 related articles for article (PubMed ID: 12456073)
1. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies?
Münch G; Deuther-Conrad W; Gasic-Milenkovic J
J Neural Transm Suppl; 2002; (62):303-7. PubMed ID: 12456073
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation endproducts in ageing and Alzheimer's disease.
Münch G; Thome J; Foley P; Schinzel R; Riederer P
Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease.
Wong A; Lüth HJ; Deuther-Conrad W; Dukic-Stefanovic S; Gasic-Milenkovic J; Arendt T; Münch G
Brain Res; 2001 Nov; 920(1-2):32-40. PubMed ID: 11716809
[TBL] [Abstract][Full Text] [Related]
5. The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development.
Copani A; Guccione S; Giurato L; Caraci F; Calafiore M; Sortino MA; Nicoletti F
Curr Med Chem; 2008; 15(24):2420-32. PubMed ID: 18855671
[TBL] [Abstract][Full Text] [Related]
6. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies.
Hölscher C
Rev Neurosci; 2005; 16(3):181-212. PubMed ID: 16323560
[TBL] [Abstract][Full Text] [Related]
7. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
Dukic-Stefanovic S; Schinzel R; Riederer P; Münch G
Biogerontology; 2001; 2(1):19-34. PubMed ID: 11708614
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts.
Münch G; Schinzel R; Loske C; Wong A; Durany N; Li JJ; Vlassara H; Smith MA; Perry G; Riederer P
J Neural Transm (Vienna); 1998; 105(4-5):439-61. PubMed ID: 9720973
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress in Alzheimer disease.
Gella A; Durany N
Cell Adh Migr; 2009; 3(1):88-93. PubMed ID: 19372765
[TBL] [Abstract][Full Text] [Related]
10. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease.
Münch G; Gasic-Milenkovic J; Arendt T
J Neural Transm Suppl; 2003; (65):63-71. PubMed ID: 12946049
[TBL] [Abstract][Full Text] [Related]
11. Anti-AGEing defences against Alzheimer's disease.
Münch G; Kuhla B; Lüth HJ; Arendt T; Robinson SR
Biochem Soc Trans; 2003 Dec; 31(Pt 6):1397-9. PubMed ID: 14641072
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.
Rahmadi A; Steiner N; Münch G
Clin Chem Lab Med; 2011 Mar; 49(3):385-91. PubMed ID: 21275816
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain.
Kuhla A; Ludwig SC; Kuhla B; Münch G; Vollmar B
Neurobiol Aging; 2015 Feb; 36(2):753-61. PubMed ID: 25448604
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
Münch G; Cunningham AM; Riederer P; Braak E
Brain Res; 1998 Jun; 796(1-2):307-10. PubMed ID: 9689484
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology.
Münch G; Apelt J; Rosemarie-Kientsch-Engel ; Stahl P; Lüth HJ; Schliebs R
J Neurochem; 2003 Jul; 86(2):283-9. PubMed ID: 12871569
[TBL] [Abstract][Full Text] [Related]
18. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress.
Perluigi M; Joshi G; Sultana R; Calabrese V; De Marco C; Coccia R; Butterfield DA
Neuroscience; 2006; 138(4):1161-70. PubMed ID: 16427207
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestation of AGE-RAGE Axis in Neurodegenerative and Cognitive Impairment Disorders.
Naz S; Mahmood T; Gupta R; Siddiqui MH; Ahsan F; Ansari VA; Shamim A; Rizvi AA
Drug Res (Stuttg); 2023 Jul; 73(6):309-317. PubMed ID: 37040870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
